SCHEMBL26144367

SCHEMBL26144367

COc1cc(CBr)c(C)cn1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NNMT P40261 1/20 0.42
LOX P28300 1/20 0.34
LOXL2 Q9Y4K0 1/20 0.34
MTNR1A P48039 2/20 0.34
MTNR1B P49286 2/20 0.34
MEN1 O00255 1/20 0.33
PABPC1 P11940 1/20 0.33
KMT2A Q03164 1/20 0.33
CYP2A6 P11509 1/20 0.33
GABRP O00591 1/20 0.33
GABRD O14764 1/20 0.33
GABRA1 P14867 1/20 0.33
GABRB1 P18505 1/20 0.33
GABRG2 P18507 1/20 0.33
GABRB3 P28472 1/20 0.33
GABRA5 P31644 1/20 0.33
GABRA3 P34903 1/20 0.33
GABRA2 P47869 1/20 0.33
GABRB2 P47870 1/20 0.33
GABRA4 P48169 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22145202 0.85 NNMT (0.46) NNMTLOXLOXL2MEN1PABPC1
SCHEMBL22570336 0.82 NNMT (0.47) NNMTLOXLOXL2MTNR1AMTNR1B
SCHEMBL17051316 0.81 NNMT (0.40) NNMTLOXLOXL2MTNR1AMTNR1B
SCHEMBL9013521 0.81 NNMT (0.35) NNMTLOXLOXL2MTNR1AMTNR1B
SCHEMBL30486638 0.81 NNMT (0.35) NNMTLOXLOXL2MTNR1AMTNR1B
SCHEMBL30240885 0.79 CYP3A4 (0.37) NNMTLOXLOXL2MTNR1AMTNR1B
SCHEMBL6794136 0.77 TUBB4A (0.39) NNMTLOXLOXL2TUBB4ATUBB
SCHEMBL22122764 0.76 HTR1A (0.34) NNMTLOXLOXL2MTNR1AMTNR1B
SCHEMBL21259587 0.75 UHRF1 (0.46) CYP2A6
SCHEMBL2614474 0.74 NNMT (0.55) NNMTLOXLOXL2MEN1PABPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11649233-B2 Halo-allylamine SSAO/VAP-1 inhibitor and use thereof NANJING TRANSTHERA BIOSCIENCES CO., LTD. (CN) 2023-05-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11649233-B2 Halo-allylamine SSAO/VAP-1 inhibitor and use thereof VAPB, VAPA, ADRA1D NNMT 2450/4885LOX 727/4885LOXL2 1155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.